Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials.

ABSTRACT:

Objective

To describe predominantly persistent subretinal fluid (SRF) in eyes receiving ranibizumab or bevacizumab for neovascular age-related macular degeneration and to compare visual acuity (VA) to eyes with nonpersistent SRF.

Design

Cohort within randomized clinical trial.

Participants

Comparison of Age-related Macular Degeneration Treatments Trials patients assigned to pro re nata treatment.

Methods

Graders evaluated monthly OCT scans for SRF. Predominantly persistent SRF through week 12 was defined as SRF at baseline and weeks 4, 8, and 12. Predominantly persistent SRF through 1 or 2 years was defined as SRF in 80% or more of visits by years 1 or 2, respectively. Linear regression models including baseline predictors of VA and predominantly persistent int

SUBMITTER: Core JQ 

PROVIDER: S-EPMC8478884 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature